Current Hepatitis Reports

, Volume 5, Issue 1, pp 14–22

Newer antiviral agents and therapeutic approaches for chronic hepatitis b

Article

Abstract

A new era in the treatment of chronic hepatitis B began approximately a decade ago. Three oral nucleoside or nucleotide analogues—lamivudine, adefovir dipivoxil, and entecavir—are now approved in the United States for the treatment of chronic hepatitis B. Other new oral agents, including telbivudine, clevudine, and emtricitabine, are in various stages of clinical investigation. This article reviews the efficacy and resistance data of these oral antiviral agents, and the preliminary results of combination therapy for chronic hepatitis B.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lok ASF, McMahon BJ: Chronic hepatitis B: Update of recommendations. Hepatology 2004, 39:857–861. A detailed summary of the American Association of the Study of Liver Diseases Practice Guidelines, focusing on the indications and end points of treatment for chronic hepatitis B infection (HBeAg positive or negative). As more treatment options and new data are rapidly emerging, some of the guidelines may soon need to be updated.PubMedCrossRefGoogle Scholar
  2. 2.
    Niedarau C, Heintges T, Lange S, et al.: Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 30:1422–1427.CrossRefGoogle Scholar
  3. 3.
    Wong DLH, Cheung AM, O’Rourke KO, et al.: Effect of alpha-interferon treatment in patients with hepatitis B e-antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med 1993, 119:312–323.PubMedGoogle Scholar
  4. 4.
    Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigennegative chronic hepatitis B. Hepatology 2001, 34:617–624.PubMedCrossRefGoogle Scholar
  5. 5.
    Lai CL, Chien RN, Leung NW, et al.: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998, 339:61–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment of patients with chronic hepatitis B virus in the United States. N Engl J Med 1999, 341:1256–1263. This multicenter randomized controlled trial of 1 year of lamivudine in patients with HBeAg-positive chronic hepatitis B infection showed very similar results compared with the study by Lai et al. [5]. The results of these two studies led to the approval of lamivudine by the FDA as the first oral agent for the treatment of chronic hepatitis B infection.PubMedCrossRefGoogle Scholar
  7. 7.
    Perrillo RP, Lai CL, Liaw YF, et al.: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36:186–194.PubMedCrossRefGoogle Scholar
  8. 8.
    Leung NWY, Lai CL, Chang TT, et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527–1532.PubMedCrossRefGoogle Scholar
  9. 9.
    Chang TT, Lai CL, Chien RN, et al.: Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004, 19:1276–1282.PubMedCrossRefGoogle Scholar
  10. 10.
    Dienstag JL, Cianciara J, Karayalcin S, et al.: Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37:748–755.PubMedCrossRefGoogle Scholar
  11. 11.
    Song BC, Suh DJ, Lee HC, et al.: Hepatitis B e antigen seroconversion after lamivudine is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000, 32:803–806.PubMedCrossRefGoogle Scholar
  12. 12.
    van Nunen AB, Hansen BE, Suh DJ, et al.: Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003, 52:420–424.PubMedCrossRefGoogle Scholar
  13. 13.
    Chien RN, Yeh CT, Tsai SL, et al.: Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003, 38:1267–1273.PubMedCrossRefGoogle Scholar
  14. 14.
    Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999, 29:889–896.PubMedCrossRefGoogle Scholar
  15. 15.
    Papatheodoridis GV, Dimou E, Laras A, et al.: Course of virologic breakthrough under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002, 36:219–226.PubMedCrossRefGoogle Scholar
  16. 16.
    Di Marco V, Marzano A, Lampertico P, et al.: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virologic response to lamivudine. Hepatology 2004, 40:883–891.PubMedCrossRefGoogle Scholar
  17. 17.
    Liaw YF, Sung JJY, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521–1531. This large randomized controlled study suggests that lamivudine treatment in patients with advanced fibrosis and cirrhosis decreases the risk for hepatic decompensation and hepatocellular carcinoma. Further studies are needed to determine if the same benefits are associated with other nucleoside or nucleotide analogues with a lower rate of drug resistance than lamivudine.PubMedCrossRefGoogle Scholar
  18. 18.
    Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808–816. This multicenter randomized controlled study established the safety and efficacy of 1 year of adefovir treatment at 10 mg/d in patients with HBeAg-positive chronic hepatitis B infection.PubMedCrossRefGoogle Scholar
  19. 19.
    Marcellin P, Chang TT, Lim S, et al.: Long-term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time [abstract]. Hepatology 2004, 40(suppl 1):655A.Google Scholar
  20. 20.
    Hadziyannis SJ, Tassopoulos NC, Heathcoate EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800–807. This multicenter randomized controlled study established the safety and efficacy of 1 of year adefovir at 10 mg/d in patients with HBeAg-negative chronic hepatitis B.PubMedCrossRefGoogle Scholar
  21. 21.
    Hadziyannis S, Tassopoulos N, Chang TT, et al.: Three-year study of adefovir dipivoxil shows sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study [abstract]. Gastroenterology 2004, 126(suppl 2):A-682.Google Scholar
  22. 22.
    Qi X, Snow A, Thibault V, et al.: Week 144 resistance surveillance of adefovir dipivoxil-treated chronic hepatitis B patients. Gastroenterology 2004, 126(suppl 2):A-660.Google Scholar
  23. 23.
    Locarnini S, Qi X, Arteburn S, et al.: Incidence and predictors of emergence of HBV mutation associated with ADV resistance during 4 years of ADV therapy for patients with chronic hepatitis B [abstract]. J Hepatol 2005, 42(suppl 2):17.Google Scholar
  24. 24.
    Angus P, Vaughan R, Xiong S, et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125:292–297.PubMedCrossRefGoogle Scholar
  25. 25.
    Perrillo R, Hann HW, Mutimer D, et al.: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004, 126:81–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Peters MG, Mann HW, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91–101.PubMedCrossRefGoogle Scholar
  27. 27.
    Lai CL, Rosmawati M, Lao J, et al.: Entecavir is superior to lamivudine in reducing HBV DNA in patients with chronic hepatitis B infection. Gastroenterology 2002, 123:1831–1838.PubMedCrossRefGoogle Scholar
  28. 28.
    Chang T, Gish R, De Man R, et al.: Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: Results of phase III study ETV-022 in nucleoside-naïve patients [abstract]. Hepatology 2004, 40(suppl 1):193A.Google Scholar
  29. 29.
    Shoval D, Lai CL, Cheinquer H, et al.: Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg(-) chronic hepatitis B: results of a phase III trial ETV-027 [abstract]. Hepatology 2004, 40(suppl 1):728A.Google Scholar
  30. 30.
    Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory HBeAg(+) chronic hepatitis B: results of a phase III study ETV-026 [abstract]. Hepatology 2004, 40(suppl 1):664A.Google Scholar
  31. 31.
    Colonno RJ, Rose R, Levine SM, et al.: Emergence of entecavir resistance hepatitis B virus after one year of therapy in phase II and III studies is only observed in lamivudine refractory patients [abstract]. Hepatology 2004, 40(suppl 1):661A.Google Scholar
  32. 32.
    Lai CL, Lim SG, Brown NA, et al.: A dose-.nding study of once daily oral Telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004, 40:719–726.PubMedCrossRefGoogle Scholar
  33. 33.
    Han SH, Leung NWY, Teo EK, et al.: Results of a one-year international phase IIB trial of LdT, and LdT plus lamivudine, in patients with chronic hepatitis B [abstract]. J Hepatol 2004, 40(suppl 1):16.CrossRefGoogle Scholar
  34. 34.
    Poynard T, Lai CL, Leung NWY, et al.: Improving antiviral therapy in chronic hepatitis B: Maximal viral suppression at week 24 correlates with better clinical efficacy at one year [abstract]. J Hepatol 2004, 40(suppl 1):130.CrossRefGoogle Scholar
  35. 35.
    Lim SG, Lai CL, Myers M, et al.: Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B [abstract]. J Hepatol 2005, 42(suppl 2):16.Google Scholar
  36. 36.
    Afdhal NH, O’Brien CB, Oshana SC, et al.: Potent anti-HBV activity of ACH-126,443 correlated with 14-day pharmacokinetics and safety: predictions for activity against YMDD mutant strains [abstract]. Hepatology 2002, 36:372A.Google Scholar
  37. 37.
    Marcellin P, Mommeja-Marin H, Sacks SL, et al.: A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004, 40:140–148.PubMedCrossRefGoogle Scholar
  38. 38.
    Chu CK, Boudinot FD, Peek SF, et al.: Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998, 3(suppl 3):113–121.PubMedGoogle Scholar
  39. 39.
    Lee HS, Chung YH, Lee KS, et al.: A 12-week clevudine therapy showed durable antiviral activity and normalization of alanine transaminase levels for 6 months after discontinuation of treatment in patients with chronic hepatitis B [abstract]. Hepatology 2004, 40(suppl 1):652A.Google Scholar
  40. 40.
    Gish RG, Leung NWY, Wright TL, et al.: Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002, 46:1734–1740.PubMedCrossRefGoogle Scholar
  41. 41.
    Leung N, Gish RG, Wang C, et al.: A randomized, doubleblind comparison of 3 doses of emtricitibine treatment in patients with chronic hepatitis B given 48 weeks of treatment [abstract]. Hepatology 2001, 34:349A.Google Scholar
  42. 42.
    Gish R, Leung N, Wang C, et al.: Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years [abstract]. Hepatology 2002, 36:372A.Google Scholar
  43. 43.
    Shiffman ML, Ng TM, Krastev Z, et al.: A double-blind, placebo-controlled trial of emtricitibine (FTC, Emtriva) administered once daily for the treatment of chronic hepatitis B virus (HBV) infection [abstract]. Hepatology 2004, 40(suppl 1):172A.Google Scholar
  44. 44.
    Benhamou Y: Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis 2004, 38(suppl 2):S98-S103.PubMedCrossRefGoogle Scholar
  45. 45.
    van Bommel F, Wunsche T, Mauss S, et al.: Comparison of adefovir and tenofovir in the treatment of lamivudineresistant hepatitis B virus infection. Hepatology 2004, 40:1421–1425.PubMedCrossRefGoogle Scholar
  46. 46.
    Lin CC, Lai MY, Chang TT, et al.: Safety, tolerance, pharmacokinetics and pharmacodynamics of remofovir, a liver-targeting prodrug of PMEA in HBV patients following daily dosing for 28 days [abstract]. Hepatology 2004, 40(suppl 1):658A.Google Scholar
  47. 47.
    Sung JJY: A randomized double blind phase II study of lamivudine compared with lamivudine plus adefovir dipivoxil for treatment-naïve patients with chronic hepatitis B: week 52 analysis [abstract 4313]. Paper presented at the 38th Annual Meeting of the European Association for the Study of the Liver (EASL). Geneva, Switzerland; July 3–6, 2003.Google Scholar
  48. 48.
    Lau GKK, Cooksley H, Ribeiro RM, et al.: Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg (+) chronic hepatitis B: efficacy and mechanisms of treatment response [abstract]. Hepatology 2004, 40(suppl 1):272A.Google Scholar
  49. 49.
    Cooksley WG: Treatment of hepatitis B with interferon and combination therapy. Clin Liver Dis 2004, 8:353–370.PubMedCrossRefGoogle Scholar
  50. 50.
    Cooksley WG, Piratvisuth T, Lee SD, et al.: Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003, 10:298–305.PubMedCrossRefGoogle Scholar
  51. 51.
    Janssen HL, van Zonneveld M, Senturk H, et al.: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005, 365:123–129. In patients with HBeAg-positive chronic hepatitis B infection, 1 year of pegylated IFN treatment led to a significantly higher rate of HBeAg seroconversion than 1 year of lamivdine. However, one may argue that longer duration of treatment for 2 to 3 years with lamivudine or other nucleoside or nucleotide analogues will have the same efficacy as 1 year of pegylated IFN treatment. This study also showed no clear advantage of combination therapy with pegylated IFN and lamivudine compared with pegylated IFN alone.PubMedCrossRefGoogle Scholar
  52. 52.
    Lau GKK, Piratvisuth T, Luo KX, et al.: Peginterferon alfa-2a (40KD) (Pegasys) monotherapy in combination with lamivudine is more effective than lamivudine monotherapy in HbeAg-positive chronic hepatitis B: Results from a large multinational study [abstract]. Hepatology 2004, 40(suppl 1):171A.Google Scholar
  53. 53.
    Chan HL, Leung NW, Hui AY, et al.: A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005, 142:240–245.PubMedGoogle Scholar
  54. 54.
    Marcellin P, Lau GKK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206–1217. Patients with HBeAg-negative chronic hepatitis B usually require long-term or indefinite treatment with a nucleoside or nucleotide analogue. In this study, 1 year of pegylated IFN treatment resulted in more sustained virologic response than 1 year of lamivudine in HBeAg-negative patients. However, combination therapy did not appear to yield added benefit compared with pegylated IFN alone.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Department of GastroenterologyUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations